Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
about
The Philadelphia chromosome in leukemogenesisCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaBiosensors in clinical practice: focus on oncohematology.Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumorsSHORT syndrome in a two-year-old girl - case report.SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.Taking aim at Alzheimer's disease through the mammalian target of rapamycinInhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.mTOR: on target for novel therapeutic strategies in the nervous system.Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsTargeted drug discovery for pediatric leukemia.Integration of Different "-omics" Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia CellsAnalysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALLDissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Resveratrol inhibits the phosphatidylinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line.Study on the function and mechanism of atorvastatin in regulating leukemic cell apoptosis by the PI3K/Akt pathway.Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia.Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway.Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Pantoprazole Induces Apoptosis of Leukemic Cells by Inhibiting Expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling.A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.Gelidiella acerosa inhibits lung cancer proliferation.Metformin, an Anti-diabetic Drug to Target Leukemia
P2860
Q26745531-25211E7E-E0D7-4B84-B1A9-E0E40AD1024AQ27025242-84513777-04B5-49BE-B952-23C4B8EDB37FQ27027114-8328C3A9-D1A9-4E63-9044-E3550903F8C6Q33411585-ECA91583-57FD-48AB-9D55-567163BB265BQ33435808-8E928300-8523-4986-B9AB-A57A660A4FD3Q33640546-7BFB8C9C-4F11-403F-928B-FCD30A92BEC8Q34356687-5220E31F-F1A2-42C8-8E2B-35DBC971DCA2Q34603651-E6567CF5-5EF3-48C7-9B04-47113CD4440AQ34704903-7F03CB0D-1C8D-4601-A55C-97EFE23EEC44Q35070321-438FE21F-6759-4A57-A175-073199A85FD1Q35606589-3DFD16FA-9A2D-4502-A539-51277B747D94Q35835131-B7662FC8-9810-4DCE-86C6-AB48B071E739Q36378398-9172F6B7-0718-4C12-9BF9-1E3DF5527A1CQ36379761-FA177757-3040-4592-B3DA-B885BE2ADAC9Q36443121-90180BA7-71BB-4D8B-82AD-A4D718A04509Q36501214-29B25870-2967-4360-B112-FF50A05D8A0AQ36591877-18C55BC1-4E50-4121-A394-497BDECD0ADDQ36640327-AE7A1FCE-E20E-4969-BD48-BC4A586D2350Q36688035-1B7AAB3A-C9E5-4FD0-916E-ED3AF43395E8Q36740744-8BE5A98F-61CB-46C6-8033-8FDC2368A2F2Q36989223-FB1FE20D-7A2F-445B-9776-1C68E4FB51F9Q36990482-DDA5A926-A459-4C8C-A028-DC1F1598FEDCQ37146303-E1CE91AE-7F4E-4DBF-9407-57DFFEEF58FEQ38103561-09939819-BEFC-45B6-B4D4-69859A99CB60Q38218128-B517A910-DF1B-4822-8430-C7A5C91D9F60Q38381981-42B76ACA-C5FD-4CB7-8843-447E9DE2728AQ38984415-FFC39876-248A-467E-9127-4BA80FEEC960Q41042432-107F7205-8AAB-40D0-BF8F-587194A7DA78Q41090525-573B8A2C-C531-49FE-B1D5-835857A5235AQ41623491-8A70BD94-16A6-49D5-86B3-ED72B50AD66FQ41958665-240A8574-AC62-4AC7-BF28-BAF5073499F3Q47203479-BD246491-6A83-4A79-A466-490D33B08750Q47597731-6E10251B-28BD-407B-BDE1-F6E995CC2564Q49556327-3207645E-DE0E-49C7-B09F-7420A432A3B1Q54120349-73F02FCA-43E2-41A9-BC38-D1EFB2754FF8Q58790135-4F99E601-7A9B-483C-990B-F1BB865CD3A8
P2860
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@ast
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@en
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@nl
type
label
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@ast
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@en
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@nl
prefLabel
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@ast
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@en
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@nl
P2093
P2860
P3181
P1433
P1476
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
@en
P2093
David Barrett
Stephan A Grupp
Valerie I Brown
P2860
P304
P3181
P356
10.2165/11594740-000000000-00000
P407
P577
2012-10-01T00:00:00Z
P6179
1069132280